NeuroSense Therapeutics Ltd. Files Form 6-K: Major ALS Treatment Update!

Here are the key points extracted from the financial report of NeuroSense Therapeutics Ltd. (Form 6-K):

1. Filing Type and Date:

• This is a Form 6-K filed with the SEC on December 23, 2024.

2. Company Information:

• Name: NeuroSense Therapeutics Ltd.
• Address: 11 HaMenofim Street, Building B, Herzliya 4672562, Israel.
• Phone: +972-9-7996183.
• SEC Commission File Number: 001-41084.

3. Content of the Report:

• The report includes a press release titled "NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS," indicating a significant corporate development related to their product PrimeC aimed at treating Amyotrophic Lateral Sclerosis (ALS).
• The press release is attached as Exhibit 99.1.

4. Incorporation by Reference:

• The information contained in this report and the specified paragraphs of the press release are incorporated into the company's existing Registration Statements on Forms S-8 and F-3, which allows this information to be considered part of those filings.

5. Signatory:

• The report is signed by Alon Ben-Noon, who is the Chief Executive Officer of NeuroSense Therapeutics Ltd.

6. Exhibit Index:

• Exhibit 99.1 is a press release detailing the binding term sheet for PrimeC, which suggests potential advancements in the company's product offerings and possibly its market position.

This report suggests a strategic move by NeuroSense Therapeutics to further develop and potentially commercialize its treatment for ALS, which could impact its market valuation and investor interest.